Preventive Effect of Lamivudine to HBV Hepatitis of Tumor Patients with HBV Infection
ZHANG Aimin*,ZEN Xianqing,YE Sheng.*Department of Oncology,Tingzhou Hospital of Fujian Provine 366300
Objective: To observe lamivudine's preventive effect to post-chemotherapy HBV hepatitis of tumor patients with HBV infection.Methods: Thirty-eight malignant tumor patients with HBV infection were divided into two groups randomly.Lamivudine 100 mg per day together with combined chemotherapy were given orally once daily in group A,meanwhile only combined chemotherapy was given in group B.Results:The peak values of total serum bilirubin(TSB) and alanine aminotransferase(ALT) before and after chemotherapy in group A were(17.9±3.8)μmol/L and(20.2±7.4) μmol/L(P 0.05),(33.7±7.5)U/L and(60.2±20.8)U/L(P 0.05);in group B were(18.1±4.3)μmol/L and(59.3±35.1)μmol/L(P 0.05),(31.9±8.8)U/L and(417.2±185.1)U/L(P 0.01),respectively.The peak values of TSB and ALT after chemotherapy in group A were of significant differences with that in group B.Three weeks after chemotherapy the HBV-DNA indexes gradually decreased in group A,but increased in group B.The negative rates of HBV-DNA index were 60% and 82% after lamivudine treatment for six weeks and eighteen weeks,respectively.Worse liver function values were observed in 3(15.8%) and 17(89.5%) patients in group A and B(P 0.01).Chemotherapy postponement was observed in 1(5.3%) and 7(36.8%)patients in group A and B.Three patients in group B had to cease chemotherapy because of worse liver function(P0.01).Conclusion: Lamivudine is effective in suppressing duplication of HBV-DNA in these tumor patients,and can prevent the onset of post-chemotherapy HBV hepatitis.
【CateGory Index】： R730.5